For the first time in Central Asia, the Scientific Center of Pediatrics and Children’s Surgery has launched a high-tech organ-preserving treatment of selective intra-arterial chemotherapy of retinoblastoma, which allows you to preserve the eye and even vision.
Retinoblastoma accounts for 90% of intraocular neoplasms in children and is characterized by high malignancy. Retinoblastoma is characterized by an aggressive course with filling the entire eyeball with tumor tissue, invading the optic nerve, orbit, and the brain. The tumor poses a threat not only in the form of loss of vision, but also in the form of high mortality due to metastasis and the development of second malignant neoplasms in other organs. Every year, 8100 new cases of retinoblastoma are diagnosed in the world, of which 570-810 are cases at birth.
Annually in the Republic of Kazakhstan 20-25 new cases of retinoblastoma are detected. Since 2015, all patients with retinoblastoma have been treated at the Scientific Center of Pediatrics and Children’s Surgery. Together with the Kazakh Research Institute of Eye Diseases, the Center introduced such organ-preserving methods of treatment as laser transpupillary thermotherapy, intravitreal chemotherapy, cryodestruction, and now selective intra-arterial chemotherapy.
Selective intra-arterial chemotherapy for 15 years of use in the USA and European countries and 10 years of use in Russia has shown high efficiency, allows you to save the eye as an organ, and even vision. In the United States, over the years of use, the number of operations to remove the eyeball has decreased from 95% to 8%.
Parents of children with retinoblastoma, in an effort to save their eyes, previously went to foreign treatment, at the expense of a foreign quota or their own funds. Now patients in our country have the opportunity to receive all types of organ-preserving treatment of retinoblastoma free of charge at the expense of the guaranteed volume of medical care.
“The Center has all the conditions for carrying out operations - special medical equipment, apparatus and trained specialists. We have been going for this day for 5 years. This is a unique event for us and for parents. For the first time in Kazakhstan, an organ-preserving operation SIACHT has been started. In November 2016, an application was submitted for consideration of a new SIACHT technology for retinoblastoma. Due to the pandemic, the clinical protocol was approved only on August 25, 2021. During this time, we conducted 2 master classes, 12 children were operated on, ”said ophthalmologist Elena Tyan.
In the photo, a team of doctors: Alua Aubakirova, Aziz Onlasynov, Elena Tyan, Darkhan Amaniyazov
#Uniquenews
#retinoblastoma
#newgrowthsinchildren